SavedAdd your journal

Journals / BEYOGLU EYE JOURNAL / 2019 / Cilt: 4 - Sayı: 2

Acute Bilateral External Ophthalmoplegia in Miller Fisher Syndrome

Feyza ÇALIŞ KARANFİL
Huban ATİLLA
Pages
123–125
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

She was treated with intravenous immunoglobulin and completely recovered in 8 weeks.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Miller Fischer syndrome is a rare entity characterized by the triad of external ophthalmoplegia, ataxia, and areflexia.
📊
Key Findings & Data:Presently described is the case of a 68-year-old woman who presented with bilateral, external ophthalmoplegia, areflexia, and ataxia.
💡
Conclusion & Impact:She was treated with intravenous immunoglobulin and completely recovered in 8 weeks.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Miller Fischer syndrome is a rare entity characterized by the triad of external ophthalmoplegia, ataxia, and areflexia. It is thought to be a form of Guillain-Barre syndrome. Presently described is the case of a 68-year-old woman who presented with bilateral, external ophthalmoplegia, areflexia, and ataxia. After excluding other conditions, a diagnosis of Miller Fisher syndrome was made. She was treated with intravenous immunoglobulin and completely recovered in 8 weeks.

🔖

Cite This Article

KARANFİL, F. Ç., ATİLLA, H. (2019). Acute Bilateral External Ophthalmoplegia in Miller Fisher Syndrome. BEYOGLU EYE JOURNAL, Cilt: 4 - Sayı: 2, 123–125. https://ajindex.com/articles/144726

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255:57–65.
  2. Mori M, Kuwabara S, Yuki N. Fisher syndrome: clinical features, immunopathogenesis and management. Expert Rev Neurother 2012;12:39–51. Van der Meché FG, Van Doorn PA, Meulstee J, Jennekens FG; GBS-consensus group of the Dutch Neuromuscular Research Support Centre. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 2001;45:133–9.
  3. Nitta T, Kase M, Shinmei Y, Yoshida K, Chin S, Ohno S. My-driasis with light-near dissociation in Fisher's Syndrome. Jpn J Ophthalmol 2007;51:224–7.
  4. Yuki N, Taki T, Takahashi M, Saito K, Yoshino H, Tai T, et al. Molecular mimicry between GQ1b ganglioside and lipopolysac-charides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994;36:791–3.
  5. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911–7.
  6. Uncini A, Lugaresi A. Fisher syndrome with tetraparesis and antibody to GQ1b: evidence for motor nerve terminal block. Muscle Nerve 1999;22:640–4.
  7. Yuan CL, Wang YJ, Tsai CP. Miller fisher syndrome: a hospital-based retrospective study. Eur Neurol 2000;44:79–85.
  8. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001;56:1104–6.
  9. Yeh JH, Chen WH, Chen JR, Chiu HC. Miller Fisher syndrome with central involvement: successful treatment with plasma-pheresis. Ther Apher 1999;3:69–71.
  10. Mori M, Kuwabara S, Fukutake T, Hattori T. Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases. J Neu-rol Neurosurg Psychiatry 2002;72:680. Bai HX, Wang ZL, Tan LM, Xiao B, Goldstein JM, Yang L. The effectiveness of immunomodulating treatment on Miller Fisher syndrome: a retrospective analysis of 65 Chinese patients. J Pe-ripher Nerv Syst 2013;18:195–6.
  11. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous im-munoglobulin therapy for Miller Fisher syndrome. Neurology 2007;68:1144–6.